Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Peter Singleton who wrote (4938)	7/22/1998 2:08:00 AM
From: Steve Fancy	Read Replies (1) \| Respond to of 6136

Thanks for all the information Peter. And you did that without notes? My feeling from what you have said, and assuming this is the big news announcement, is that it will be perceived as yet another disappointment. I believe I've read in black and white recently that folks were looking for news to offset the R&D costs of the three new compounds. Their reasoning was to create recognition for their cancer drugs? Do you know which drugs specifically? On one hand this displays a little more faith in their potential than displayed recently by AGPH, on the other hand, raises a lot of questions as to what might be taken away from a current shareholder if anything, and will it even begin to offset R&D costs next year for the three recently licensed compounds. Did they get into this at all? Maybe we'll all be lucky and the stock will go against my expectations tomorrow, but barring any further news, I expect the stock may be trading under $30 for a while longer. Thanks again Peter. sf